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It was at the suggestion of Professor Michael Whitehouse
(see previous Editorial) that I should give a brief account of
how the journal was started, the raison d’etre for its exis-
tence, and now 25 years since it was first published what
the future holds for this multi-disciplinary journal.
The beginnings of inflammopharmacology (IPH) started
when Dr. Peter Clarke, a commissioning editor from MTP
(Lancaster, UK, later taken over by Kluwer) came to my
laboratory in Cambridge in 1988 and asked if I would be
interested in establishing a new journal for publishing papers
in the general area of the pharmacology of inflammation. I
was about to take up a new post as a joint professor in
Biomedical Sciences (Pharmacology) and Pathology at
McMaster University Faculty of Health Sciences in Hamil-
ton, Ontario, Canada. The thought of trying to establish a
new journal while at the same time setting up new research
programmes and collaborations, teaching medical and
biomedical subjects, and promoting the development of a
Pharmacology of Rheumatic Diseases group presented a
daunting, if not formidable prospect. However, after dis-
cussing the ideas and working out what could be done with
colleagues it seemed to be a worthwhile project. My col-
leagues at McMaster University were particularly
enthusiastic, among them Professors Watson Buchanan,
Walter Kean, Richard Hunt and Alan McComas.
By 1991, we had published the first issues of volume
1 (Table 1) and interest in the journal progressively
developed. The first publisher, Kluwer Academic (Dor-
drecht, The Netherlands) produced six volumes up until
1998. Subsequently, this publisher handed over the
publication to another Dutch publisher, VSP (http://
www.vsp.com; Utrecht) who continued later as part of
Koninklinje Brill NV until volume 13 was published in
2005 (Table 2). Considerable interest had developed at
this stage thanks to the support of a widening Editorial
Board, special issues devoted to topical subjects, and
publication of peer-reviewed papers selected from con-
ferences on the ‘‘Side Effects of Anti-inflammatory
Drugs (SEADs) and later the ‘‘Inflammopharmacology’’
series (Table 2).
A matter of concern then to me was that the previous
publishers had not been able to get a journal cited in Index
Medicus (PubMed) or the Institute for Scientific Informa-
tion (ISI) Web of Science. I was not appraised of the
situation about citation on these indexes. I had discussed
the issue about how the future development of the journal
could be progressed and the citation issue with a consid-
erable number of scientists, physicians in the field of
gastroenterology, rheumatology and internal medicine, as
well as with academic publishers. I had decided that we
needed to seek a publisher who would have the experience
of publishing research in the field of inflammation and who
had the facilities to make the wider scientific and medical
world aware of the journal, to promote its interests and to
seek citation and impact factor ratings. By good luck, I was
participating in a conference in Rome in 2005 at which my
wife and I were having lunch in which Dr. Detlef Klu¨ber
from Birkha¨user Verlag, Basel, was at our table when
discussion took place about journal publications. I had
known Dr. Klu¨ber from being previously involved with
him in book publications. My wife suggested to me that
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Table 1 Titles of papers in the first volume of Inflammopharmacology
Inflammopharmacology
Vol. 1 no. 1; 1991 Contents
Editorial statement 1
Molecular pathology of drug-disease interactions in chronic autoimmune
Inflammatory diseases
A.L. Parke, D.F.V. Lewis and D.V. Parke 3
Relationship between enantiomer levels of flurbiprofen and clinical response
In rheumatoid arthritis
N. Bellamy, S. Cox and J. Campbell 37
Solcoseryl prevents inflammatory and hypoxic but not liver injury in rodents
T. Hartung, M. Leist, G. Tiegs, W. Baschong and A. Wendel 49
Conditional pharmacology: expression of anti-inflammatory activity may require
Pre-existent inflammatory mediators/hormones
M.W. Whitehouse and B. Vernon-Roberts 61
Pharmacokinetic interactions and adverse drug experiences in rheumatoid
Arthritis
D.E. Furst 69
Inflammation Research Association Meeting Report
K.D. Rainsford 79
Instructions for Authors and Editorial Policy 93
Vol. 1 no. 2; 1991 Contents
Editorial commentary 97
Editorial: the antirheumatic gold complexes: considerations of chemical form
In studies on their mechanism of action
G.G. Graham, G.D. Champion and Z.B. Ziegler 99
Gold complex research in medical science. Difficulties with experimental design
W.F. Kean, C.J.L. Lock and H. Howard-Lock 103
NSAIDs: clinical efficacy and toxicity
W.W. Buchanan and N. Bellamy 115
Interaction between flurbiprofen and H2-antagonists in rheumatoid arthritis
J.H. Kreeft, N. Bellamy, D. Freeman and J. Campbell 135
Disease-drug interaction: significance or insignificance of the ED50 value for anti-inflammatory agents
M.W. Whitehouse 143
Effect of benzydamine, a topically administered NSAID, on in vitro prostanoid
synthesis by human and rat gastric mucosa and rat kidney, aorta and urinary bladder: lack of effect on
cyclooxygenase but potent inhibition of receptor-linked prostanoid synthesis
J.Y. Jeremy, R.M. Kirk and D.P. Mikhailidis 151
Discriminating effects of a nucleotide-rich yeast extract, ProbioticumR, as an immunomodulator contrasted
with actions in chronic immuno-inflammatory disease (adjuvant-induced arthritis) in rodents
G. Burmeister and K.D. Rainsford 161
Instructions to Authors and Editorial Policy 185
Vol. 1 no. 3; 1992 Contents
Editorial commentary 191
A statistical matching of patients with dermatomyositis and polymyositis:
A preliminary feasibility study
K.E. Tymms, E.M. Beller, L. Schrieber, J. Webb and W. Watson Buchanan 195
synthesis and pharmacological evaluation of amide derivatives of non-steroidal anti-inflammatory drugs
M.-F. Otis, L. Levesque, F. Marceau, J. Lacroix and R.C.-Gaudreault 201
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Table 1 continued
Vol. 1 no. 3; 1992 Contents
Partial liver resection and inflammation: role of exogenous glucocorticoids
R. Coimbra, P. Sannomiya, S. Rasslan and J. Garcia-Leme 213
Evaluation of the inflammatory activity in rheumatoid arthritis. Nanocolloid scintigraphy vs. clinical examination and bone
scintigraphy
A. von Heijne, P. Seideman and M. Dahlborn 223
Double-blind randomized controlled trial and six-year open follow-up of yttrium-90 radiosynovectomy versus triamcinolone
hexacetonide in persistent rheumatoid knee synovitis
E.N. Grant, N. Bellamy, K. Fryday-Field, T. Disney, A. Driedger and K. Hobby 231
Report on the Third International Symposium on Gastrointestinal
Cytoprotection, Pecs, Hungary, October 7–8th, 1991
K.D. Rainsford 239
Reduction of bleomycin-induced sequestration of neutrophils and vascular injury in hamster lungs by nitroglycerin
Q. Wang, D.R. Haynam, D.M. Hyde, A.B. Combs and S.N. Giri 249
Effects of human recombinant IL-1b on established experimental arthritis in rats
E. Drelon, P. Gillet, J.Y. Jouzeau, P. Fener, A. Bousseau, G. Charrie`re,
B. Terlain and P. Netter 263
Announcement 283
Vol. 1 no. 4; 1991 Contents
Letters to the Editor 285
Paradoxical effect of dexamethasone administration to rabbits with
antigen-induced arthritis
A.J. de Brum-Fernandes, V. de Falco, F.A. Castro da rocha and S. Jancar 289
Distribution of gold in human platelets after in vitro interaction and during chrysotherapy with gold sodium thoimalate
Y.B. Kassam, W.F. Kean, C.J.L. Lock, G.T. Simon and W.W. Buchanan 295
Conditional pharmacology: II. Ambivilant effects of aurocyanide, a putative active metabolite of anti-arthritic
gold drugs, on human and rat PMN leucocytes
S.J. Gadd, M.W. Whitehouse and B. Vernon-Roberts 305
The effect of slow acting antirheumatic drugs on the production of cytokines by human monocytes
V.A. Danis, D.A. Rathjen and P.M. Brooks 315
Idiopathic chronic facial pain: tricyclic antidepressant drug action is not due to free radical scavenging (antioxidant) activity
M. Wasil, B. Henderson and M. Harris 329
Human neutrophils stimulated by cetyltrimethyl ammonium bromide generate luminol-amplified
and non-amplified chemiluminsecence but no superoxide production: a paradox
I. Ginsburg, R. Misgav, A. Samuni, D.F. Gibbs, J. Varani and R. Kohen 337
Elevation of intestinal substance P by acute acetic acid in rabbits:
Modification by infant formulas
M.J.S. Miller, M.E. Becerra, M. Wong, X.-J. Zhang, H. Sadowska-Krowicka,
D.J. Albrecht, D.A. Clark and A.Y. Jeng 353
Short communication
Observations on measurement of 2,3- and 2,5-dihydroxybenzoic acid using high performance liquid chromatography
B. Aghabeigi and B. Henderson 363
Meeting Report
First International Congress of the Worldwide Hungarian Medical Academy
K.D. Rainsford 369
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Table 2 Inflammopharmacology conference series (with side-effects of anti-inflammatory drugs symposia)
Conference details and publications of
proceedings
1. Side-Effects of Anti-Inflammatory/Analgesic Drugs
(K. D. Rainsford and G. P. Velo, Organisers)
Venue: University of Verona (Italy), September 1982
Publication, Book: Side-Effects of Anti-Inflammatory/Analgesic Drugs. Advances in inflammation
research, 6
Editors: K. D. Rainsford and G. P. Velo. Raven Press, New York, 1984
2. Side-Effects of Anti-Inflammatory Drugs
(K. D. Rainsford and G. P. Velo, Organisers)
Venue: University of Cambridge & Queens’ College, Cambridge (UK) 31st July to 2nd August,
1985
Publication, Book: Side-Effects of Anti-Inflammatory Drugs, 2 Part Volumes
Editors: K. D. Rainsford and G P Velo. MTP Press, Lancaster, 1985
3. Side-Effects of Anti-Inflammatory Drugs
(K. D. Rainsford and G P Velo, Organisers)
Venue: University of Verona (Italy), 8th–11th May, 1991
Publication, Book: Side-Effects of Anti-Inflammatory Drugs, 3
Editors: K. D. Rainsford and G. P. Velo. Kluwer Academic Publishers, Lancaster, 1992
4. Side-Effects of Anti-Inflammatory Drugs
(K. D. Rainsford, Organiser)
Venue: Sheffield Hallam University, 7–9th August, 1995
Publication, Book: Side-Effects of Anti-Inflammatory Drugs, IV
Editors: K. D. Rainsford and G. P. Velo. Kluwer Academic Publishers, Dordrecht, 1997
Publication (peer-review papers): Inflammopharmacology, Vol. 3, pp 137–204 and 311–399, 1996
5. Side-Effects of Anti-Inflammatory Drugs
(K. D. Rainsford and M C Powanda, Organisers)
Venue: South San Francisco Conference Center, 17th–19th March, 1997
Publication, Book: Safety and Efficacy of Non-Prescription (OTC) Analgesics and NSAIDs,
Editors: K. D. Rainsford and M. C. Powanda, Kluwer Academic Publishers, Dordrecht, 1998.
6. International Conference on Inflammopharmacology and 6th Symposium on Side Effects of anti-
inflammatory Drugs
Venue: Chateau Elan, Braselton. Georgia, USA, 23rd–26th may, 1999
Publication: Inflammopharmacology, Vol. 7, pp 191–303, 339–350
7. International Conference on Inflammopharmacology and 7th Symposium on Side Effects of anti-
inflammatory Drugs
Venue: Sheffield Hallam University, Sheffield, 10th–13th September, 2001
Publication: Inflammopharmacology, Vol. 9, pp 101–216
8. International Conference on Inflammopharmacology and 8th Symposium on Side Effects of anti-
inflammatory Drugs
Venue: Royal College of Physicians of Edinburgh, Edinburgh, 22nd–24th April, 2003.
Publication: Inflammopharmacology, Vol. 11, pp 301–470
9. Nineth International Conference on Inflammopharmacology
Venue: Queens’ College, University of Cambridge, Cambridge, 8th–10th September, 2008
Publication: Inflammopharmacology, Vol. 16, pp 286–324
10. 10th International Conference on Inflammopharmacology: 20 Years of Inflammopharmacology
Venue: Department of Pharmacology. University of Cambridge, Cambridge, UK. 4th–6th July 2011
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perhaps I should ask Dr. Klu¨ber if he would be interested in
publishing Inflammopharmacology. It emerged during
discussions that he was looking for complementary publi-
cations to fit with the Birkha¨user portfolio of journals that
included Inflammation Research (formerly Agents and
Actions) with whom I had previously had editorial
involvement. It seemed that the focus of Inflammophar-
macology on pharmacological aspects of the therapy of
inflammatory diseases, would be a neat complement to the
understanding of inflammatory processes which was the
focus of Inflammation Research. With my past involve-
ment in the latter journal we had the basis for developing
complementary publications and through personal contacts
via the editors we could see a basis for establishing a
working plan for both journals working independently of
one another.
After Inflammopharmacology moved to Birkha¨user, the
scientific and medical journals from this publisher were
taken over and incorporated into the portfolios of Springer
Basel AG, a subsidiary of Springer AG (Heidelberg). This
was a fortuitous development since we now had the support
of the extensive publication systems and expertise of
Springer. I would also mention that it was the enthusiasm,
expertise and invaluable support of Dr. Klu¨ber that enabled
Table 3 Most frequent citations and frequently accessed articles in Inflammopharmacology
A. Most highly cited articles in inflammopharmacology
Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, Giusti P (2014) Palmitoylethanolamide, a naturally occurring disease-
modifying agent in neuropathic pain. Inflammopharmacology 22(2):79–94
Goyal N, Rana A, Ahlawat A, Bijjem KR, Kumar P (2014) Animal models of inflammatory bowel disease: a review. Inflammopharmacology
22(4):219–33
Cock IE, van Vuuren SF (2014) Anti-Proteus activity of some South African medicinal plants: their potential for the prevention of rheumatoid
arthritis. Inflammopharmacology 22(1):23–36
Ellulu MS, Khaza’ai H, Abed Y, Rahmat A, Ismail P, Ranneh Y (2015) Role of fish oil in human health and possible mechanism to reduce the
inflammation. Inflammopharmacology 23(2–3):79–89
Bartels LE, Bendix M, Hvas CL, Jørgensen SP, Agnholt J, Agger R, Dahlerup JF (2014) Oral vitamin D3 supplementation reduces monocyte-
derived dendritic cell maturation and cytokine production in Crohn’s disease patients. Inflammopharmacology 22(2):95–103
Afzal M, Safer AM, Menon M. (2015) Green tea polyphenols and their potential role in health and disease. Inflammopharmacology
23(4):151–61
Khan N, Smith MT (2014) Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from
rodent EAE models. Inflammopharmacology 22(1):1–22
El-Agamy DS, Makled MN, Gamil NM (2014) Protective effects of agmatine against D-galactosamine and lipopolysaccharide-induced
fulminant hepatic failure in mice. Inflammopharmacology 22(3):187–94
Slomiany BL, Slomiany A. (2014) Role of ghrelin-induced phosphatidylinositol 3-kinase activation in modulation of gastric mucosal
inflammatory responses to Helicobacter pylori. Inflammopharmacology 22(3):169–77
Vitetta L, Linnane AW (2014) Endocellular regulation by free radicals and hydrogen peroxide: key determinants of the inflammatory response.
Inflammopharmacology. 22(2):69–72
B. Top 10 downloaded articles in inflammopharmacology
Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF (2013) The modern pharmacology of paracetamol: therapeutic actions,
mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 21(3):201–32
Rainsford KD (2009) Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 17(6):275–342
Vitetta L, Bambling M, Alford H (2014) The gastrointestinal tract microbiome, probiotics, and mood. Inflammopharmacology 22(6):333–9
Goyal N, Rana A, Ahlawat A, Bijjem KR, Kumar P (2014) Animal models of inflammatory bowel disease: a review. Inflammopharmacology
22(4):219–33
Ellulu MS, Khaza’ai H, Abed Y, Rahmat A, Ismail P, Ranneh Y (2015) Role of fish oil in human health and possible mechanism to reduce the
inflammation. Inflammopharmacology 23(2–3):79–89
Chan YS, Cheng LN, Wu JH, Chan E, Kwan YW, Lee SM, Leung GP, Yu PH, Chan SW (2011) A review of the pharmacological effects of
Arctium lappa (burdock). Inflammopharmacology 19(5):245–54
Maes M, Fisˇar Z, Medina M, Scapagnini G, Nowak G, Berk M. (2012) New drug targets in depression: inflammatory, cell-mediated immune,
oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and
GSK-3 inhibitors. Inflammopharmacology 20(3):127–50
Thomas S, Baumgart DC (2012) Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology
20(1):1–18
Jinesh S (2015) Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology 23(2–3):71–7
Khan MA (1999) Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharmacology. 1999 7(1):15–35. [See also
recent update: Akram Khan M, Afzal M (2016) Chemical composition of Nigella sativa Linn: Part 2 Recent advances. Inflammopharmacology
24(2–3):67–79]
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then and now to vastly improve the presentation and dis-
tribution of the journal worldwide. To me personally, Dr.
Klu¨ber has been of immense help and support in the whole
process of publishing the journal.
The quality and interest in the journal has now reached
the stage of it being recognized as a leading journal in the
field of basic and clinical research focussing on the actions
of existing and novel therapies for treating the wide range
of acute and chronic painful inflammatory diseases. This is
reflected in the frequent citations and assessing of articles
(downloads) (Table 3). From time to time we adjusted the
focus or topics that are covered in the journal in keeping
with changes in the fields of therapeutics of acute and
chronic inflammatory conditions. We hope that this journal
can continue its mission in meeting future challenges for
advancing and developing new and safer drugs for the large
number of diseases that are encompassed by ‘‘acute and
chronic inflammatory conditions’’.
The success of the journal would not have been possible
without the active support and encouragement of the spe-
cialist Editors and members of the Editorial Board.
Inflammopharmacology has always been an independent
organ without commercial support or commercial adver-
tising (aside from books or journals from Springer, which
has no financial involvement in the journal). The Editors
and Reviewers who receive no recompense are to be
thanked for their invaluable help and immense support in
ensuring selection and scrutiny of submitted papers that are
of high quality and interest to the wide readership of the
journal. We regularly monitor the standard of papers and a
measure of the value of the outputs of the journal can be
shown in the numbers of downloads and citations through
various electronic sources (PubMed, Web of Science,
Google Scholar, SciMago, etc.). There have been over
30,000 downloads of the journal articles from Springerlink
annually. PubMed and Google Scholar give the journal a
wide coverage. The most recent Thompsons Reuter’s
Impact Factor for 2015 of 2.304 is recognition that
Inflammopharmacology is widely cited and has impact
comparable with other leading journals in cognate fields.
We propose to expand the scope of the journal to
embrace (1) advances in the safe and effective therapy with
opioids, cannabinoids and other agents that affect neuro-
inflammatory and neuro-degenerative diseases; (2) the
discovery of compounds from natural products and chem-
ically designed compounds developed to act on newly
discovered inflammatory or pain-producing targets; (3)
modification of existing drugs or agents to enhance their
efficacy and reduce frequently occurring adverse or side-
effects via pharmacokinetic and/or pharmacodynamic
modifications; (4) critical review and clinical evaluation of
current drugs used to treat painful inflammatory diseases,
especially using advanced statistical procedures (e.g.
algorithms designed to be adapted to small patient numbers
or intrinsically complex conditions (back pain, neuro-
pathologic states), and (5) the accurate application of non-
selective meta- and group-analyses, and assessments of
impartial judgements of clinical data—these procedures
being employed to enable unbiased critical recognition of
those conditions that positively or negatively affect the
efficacy and safety of drugs or that may give lead for
adapting or modifying existing or novel drugs as advanced
therapeutics.
The journal will always be an open forum for critical
exploration of new ideas and objective re-evaluation of
older or established ideas and concepts.
We look forward following the first 25 years to an
exciting future from which it is hoped to discover new
approaches regulate the vast array of inflammatory pro-
cesses that underlie many diseases.
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